Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2017-10-19
Target enrollment:
Participant gender:
Summary
This is a phase 1b, dose escalation, study of quizartinib to evaluate the safety profile, the
pharmacokinetics, and the recommended dose of quizartinib for subsequent clinical studies of
the combination of quizartinib and induction and consolidation chemotherapy.